Pursuits
Bayer, Nespresso, Al Jazeera: Intellectual Property
This article is for subscribers only.
Bayer AG, Europe’s largest drug and chemical maker, lost its effort to collect patent royalties from Johnson & Johnson’s sales of rheumatoid arthritis drug Simponi.
Bayer, which sued J&J in 2009, conceded that Simponi isn’t infringing its patent under an interpretation of “human monoclonal antibodies” issued by a federal judge last month, according to a Jan. 25 court filing. Bayer’s lawsuit, terminated Jan. 28, could be revived if it wins its appeal of the ruling.